# A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy

> **NCT06602739** · PHASE3 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 54 (actual)

## Conditions studied

- Allergic Conjunctivitis

## Interventions

- **DRUG:** REGN5713
- **DRUG:** REGN5715
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06602739
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-11-19
- **Primary completion:** 2025-04-23
- **Final completion:** 2025-08-02
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06602739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06602739, "A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT06602739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*